Why These Analysts Are Backing Off Walmart Stock
Oppenheimer downgraded Walmart (WMT) to a neutral “perform” rating, withdrawing a $140 per share price target. The firm cited headwinds in the U.S. pharmacy business, a “peakish” valuation, and Street forecasts it said are ahead of Walmart’s guidance. Walmart shares are slightly down in 2026, with next quarterly results due Aug. 20.
How this was made
The 30-second read
Why it matters
A rating downgrade with a withdrawn premium target can shift positioning and raise the bar for earnings to confirm guidance, especially around pharmacy-driven same-store sales.
Market read
Traders get a concrete sell-side catalyst (downgrade and target withdrawal) and a clear earnings-risk narrative (pharmacy revenue and forecast optimism) ahead of the Aug. 20 report.
What to watch
The article does not quantify pharmacy revenue magnitude or provide updated guidance, so traders may be over-weighting the qualitative headwind versus any offsetting strength in other segments ahead of Aug. 20.
Background
The piece centers on an analyst action by Oppenheimer, framed as a step back from Walmart’s earlier outperformance case.
Ticker impact
Oppenheimer downgraded Walmart to neutral and withdrew a $140 price target, citing U.S. pharmacy revenue headwinds and valuation risk.
Bias toward underperformance versus prior expectations until earnings clarify pharmacy trends and guidance.
The article provides a specific rating change and removed price target, plus three explicit drivers (pharmacy headwinds, peakish valuation, and forecast vs guidance gap). It does not provide new company financial data, so impact is likely sentiment-driven rather than fundamental re-rating from fresh results.
Market effects
Caution on retail pharmacy-related same-store sales could pressure sentiment across large-format retailers with meaningful pharmacy exposure.
Primarily U.S. large-cap retail sentiment.
Limited direct global spillover; mostly affects U.S. consumer/retail positioning.
Counterpoint
Even with pharmacy headwinds, the analysts still call longer-term prospects upbeat, implying the downgrade may be more about valuation and near-term expectations than business deterioration.
Key entities
- public_companyWalmart
Subject of the analyst downgrade to neutral, with cited pharmacy headwinds and valuation/forecast concerns.
- analyst_firmOppenheimer
Issued the downgrade and withdrew the $140 price target.
